Considerations in the approach to invasive fungal infection in patients with haematological malignancies
- PMID: 18173752
- DOI: 10.1111/j.1365-2141.2007.06906.x
Considerations in the approach to invasive fungal infection in patients with haematological malignancies
Abstract
Invasive infections because of opportunistic yeasts and moulds have contributed significantly to the morbidity and mortality associated with potentially curative treatment for haematological malignancies. Many risk factors have been identified that permit the clinician to predict the likelihood of these infections. The diagnostic process involves maintaining a high index of suspicion based upon an understanding of the clinical circumstances under which invasive fungal infections occur, of the spectrum of fungal syndromes, and of the advantages and limitations of diagnostic testing strategies now available. Treatment strategies may be categorized as prophylactic, pre-emptive, empiric, or directed based upon the circumstances. The therapeutic options have increased in recent years but are not applicable to all clinical circumstances. These considerations are discussed.
Similar articles
-
[Mycoses and their treatment in malignant hemopathies].Recenti Prog Med. 1999 Mar;90(3):160-8. Recenti Prog Med. 1999. PMID: 10228357 Review. Italian.
-
[Invasive fungal infections in patients with hematological malignancies: a clinical approach].Med Clin (Barc). 2000 Sep 16;115(8):305-12. doi: 10.1016/s0025-7753(00)71542-9. Med Clin (Barc). 2000. PMID: 11093887 Review. Spanish. No abstract available.
-
Management of intracranial fungal infections in patients with haematological malignancies.Br J Haematol. 2005 Nov;131(3):287-300. doi: 10.1111/j.1365-2141.2005.05749.x. Br J Haematol. 2005. PMID: 16225648 Review.
-
Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients.J Clin Pathol. 2009 Jan;62(1):64-9. doi: 10.1136/jcp.2008.058354. J Clin Pathol. 2009. PMID: 19103864
-
Advances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies.Transpl Infect Dis. 2009 Dec;11(6):480-90. doi: 10.1111/j.1399-3062.2009.00441.x. Epub 2009 Sep 1. Transpl Infect Dis. 2009. PMID: 19725908 Review.
Cited by
-
Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis.Support Care Cancer. 2011 Nov;19(11):1807-13. doi: 10.1007/s00520-010-1022-7. Epub 2010 Oct 23. Support Care Cancer. 2011. PMID: 20972589
-
The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer.Infect Dis Ther. 2022 Dec;11(6):2063-2098. doi: 10.1007/s40121-022-00700-1. Epub 2022 Oct 14. Infect Dis Ther. 2022. PMID: 36229765 Free PMC article.
-
Machine learning-based combined nomogram for predicting the risk of pulmonary invasive fungal infection in severely immunocompromised patients.Ann Transl Med. 2022 May;10(9):514. doi: 10.21037/atm-21-4980. Ann Transl Med. 2022. PMID: 35928747 Free PMC article.
-
Clinical Spectrum, Diagnosis and Outcome of Rare Fungal Infections in Patients with Hematological Malignancies: Experience of 15-Year Period from a Single Tertiary Medical Center.Mycopathologia. 2020 Apr;185(2):347-355. doi: 10.1007/s11046-020-00436-x. Epub 2020 Feb 25. Mycopathologia. 2020. PMID: 32100219
-
Invasive aspergillosis due to Neosartorya udagawae.Clin Infect Dis. 2009 Jul 1;49(1):102-11. doi: 10.1086/599345. Clin Infect Dis. 2009. PMID: 19489714 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical